NewsRoom

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

201020092008

Jun 14, 2017
Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Mar 28, 2017
Live Webcast from New York on April 4th
Mar 14, 2017
Live Webcast from New York on March 21st
Feb 8, 2017
Company Begins Calendar Year with $55 Million in Cash
Dec 5, 2016
Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016
Nov 17, 2016
Live Webcast from San Diego on December 1st
Nov 9, 2016
Quarter Highlighted by Breakthrough Therapy Designation and Global Strategic Partnership for Pracinostat
Nov 7, 2016
Live Webcast from New York on November 15th
Sep 6, 2016
Company Now Well Positioned with Fully Funded, Phase III-Ready Asset, Emerging Pipeline and Strong Cash Balance
 

rss